Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years
Status:
Unknown status
Trial end date:
2020-03-30
Target enrollment:
Participant gender:
Summary
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess
the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in
subjects aged ≥12 years with moderate to severe persistent, reversible asthma.
Phase:
Phase 3
Details
Lead Sponsor:
Mundipharma (China) Pharmaceutical Co. Ltd
Treatments:
Fluticasone Fluticasone-Salmeterol Drug Combination Formoterol Fumarate Salmeterol Xinafoate Xhance